Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0D6DH
|
||||
Former ID |
DNC006034
|
||||
Drug Name |
A-432411
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C20H16N2O3
|
||||
Canonical SMILES |
COC1=C(C=CC(=C1)C2=CC3=C(C=C2)C(=CC4=CC=CN4)C(=O)N3)O
|
||||
InChI |
1S/C20H16N2O3/c1-25-19-10-13(5-7-18(19)23)12-4-6-15-16(11-14-3-2-8-21-14)20(24)22-17(15)9-12/h2-11,21,23H,1H3,(H,22,24)/b16-11-
|
||||
InChIKey |
AYSXURJZVXBSRV-WJDWOHSUSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Serine/threonine-protein kinase Chk1 | Target Info | Inhibitor | [1] | |
KEGG Pathway | Cell cycle | ||||
p53 signaling pathway | |||||
HTLV-I infection | |||||
Viral carcinogenesis | |||||
Pathway Interaction Database | Fanconi anemia pathway | ||||
p73 transcription factor network | |||||
ATR signaling pathway | |||||
Circadian rhythm pathway | |||||
p53 pathway | |||||
Reactome | Activation of ATR in response to replication stress | ||||
Processing of DNA double-strand break ends | |||||
Presynaptic phase of homologous DNA pairing and strand exchange | |||||
G2/M DNA damage checkpoint | |||||
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | |||||
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | |||||
WikiPathways | DNA Damage Response | ||||
Signaling by SCF-KIT | |||||
ATM Signaling Pathway | |||||
Retinoblastoma (RB) in Cancer | |||||
Integrated Pancreatic Cancer Pathway | |||||
Prostate Cancer | |||||
Integrated Breast Cancer Pathway | |||||
Integrated Cancer pathway | |||||
Cell Cycle | |||||
Cell Cycle Checkpoints | |||||
miRNA Regulation of DNA Damage Response | |||||
References | |||||
REF 1 | Bioorg Med Chem Lett. 2010 Sep 1;20(17):5065-8. Epub 2010 Jul 13.Synthesis of selenophene derivatives as novel CHK1 inhibitors. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.